Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

被引：0
|
作者：
T. Sakakida
T. Ishikawa
Y. Chihara
S. Harita
J. Uchino
Y. Tabuchi
S. Komori
J. Asai
T. Narukawa
A. Arai
H. Tsunezuka
T. Kosuga
H. Konishi
M. Moriguchi
H. Yasuda
F. Hongo
M. Inoue
S. Hirano
O. Ukimura
Y. Itoh
T. Taguchi
K. Takayama
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology, Graduate School of Medical Science
[2] Kyoto Prefectural University of Medicine,Outpatient Oncology Unit, University Hospital
[3] Kyoto Prefectural University of Medicine,Department of Pulmonary Medicine, Graduate School of Medical Science
[4] Kyoto Prefectural University of Medicine,Department of Dermatology, Graduate School of Medical Science
[5] Kyoto Prefectural University of Medicine,Department of Urology, Graduate School of Medical Science
[6] Kyoto Prefectural University of Medicine,Department of Otolaryngology
[7] Kyoto Prefectural University of Medicine,Head and Neck Surgery, Graduate School of Medical Science
[8] Kyoto Prefectural University of Medicine,Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science
[9] Kyoto Prefectural University of Medicine,Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science
[10] Kyoto Prefectural University of Medicine,Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Immune-related adverse events; Programmed cell death 1 blockade; Immune checkpoint inhibitors; Antinuclear antibodies; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 927
页数：8
相关论文
共 50 条
  • [1] Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
    Sakakida, T.
    Ishikawa, T.
    Chihara, Y.
    Harita, S.
    Uchino, J.
    Tabuchi, Y.
    Komori, S.
    Asai, J.
    Narukawa, T.
    Arai, A.
    Tsunezuka, H.
    Kosuga, T.
    Konishi, H.
    Moriguchi, M.
    Yasuda, H.
    Hongo, F.
    Inoue, M.
    Hirano, S.
    Ukimura, O.
    Itoh, Y.
    Taguchi, T.
    Takayama, K.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06): : 919 - 927
  • [2] Safety of PD-1/PD-L1 blockade in patients with preexisting positive antinuclear antibodies and autoimmune disease
    Sakakida, Tomoki
    Ishikawa, Takeshi
    Chihara, Yusuke
    Harita, Sachi
    Uchino, Junji
    Tabuchi, Yusuke
    Komori, Satoshi
    Asai, Jun
    Narukawa, Tsukasa
    Takata, Tomoki
    Arai, Akihito
    Tsunezuka, Hiroaki
    Kosuga, Toshiyuki
    Konishi, Hirotaka
    Hongo, Fumiya
    Inoue, Masayoshi
    Hirano, Shigeru
    Ukimura, Osamu
    Itoh, Yoshito
    Taguchi, Tetsuya
    Takayama, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
    Tang, Hui
    Geng, Ruixuan
    Xu, Xiuxiu
    Wang, Yingyi
    Zhou, Jiaxin
    Zhang, Shulan
    Zhao, Lin
    Guan, Mei
    Bai, Chunmei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [5] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Zhang, Ke
    Kong, Xiangyi
    Li, Yuan
    Wang, Zhongzhao
    Zhang, Lin
    Xuan, Lixue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [7] PD-1 and PD-L1 antibodies for melanoma
    Tsai, Katy K.
    Zarzoso, Ines
    Daud, Adil I.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
  • [8] Novel PD-1 blockade bioassay to assess therapeutic antibodies in PD-1 and PD-L1 immunotherapy programs
    Cheng, Zhi-Jie Jey
    Karassina, Natasha
    Grailer, Jamison
    Hartnett, Jim
    Fan, Frank
    Cong, Mei
    CANCER RESEARCH, 2015, 75
  • [9] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Annika De Sousa Linhares
    Claire Battin
    Sabrina Jutz
    Judith Leitner
    Christine Hafner
    Joshua Tobias
    Ursula Wiedermann
    Michael Kundi
    Gerhard J. Zlabinger
    Katharina Grabmeier-Pfistershammer
    Peter Steinberger
    Scientific Reports, 9
  • [10] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Linhares, Annika De Sousa
    Battin, Claire
    Jutz, Sabrina
    Leitner, Judith
    Hafner, Christine
    Tobias, Joshua
    Wiedermann, Ursula
    Kundi, Michael
    Zlabinger, Gerhard J.
    Grabmeier-Pfistershammer, Katharina
    Steinberger, Peter
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345